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Chronic lymphocytic leukemia (CLL) is characterized by the progressive accumulation of clonal mature B cells in the blood, bone marrow and secondary lymphoid organs. Although peripheral CLL is quiescent, up to 1% of clonal cells are generated daily within proliferative centers. 1 CLL cells isolated from these structures display activation of survival and proliferation pathways (for example, phosphatidylinositol 3-Kinase (PI3K), Bruton's tyrosine kinase (BTK) and nuclear factor (NF-kB)) 1 because of interactions with accessory cells. In CLL, B-cell receptor (BCR) signaling represents one of the central pathways known to enhance survival and proliferation.
The importance of BCR signaling in CLL pathogenesis is underscored by the prognostic significance of somatic mutations in the immunoglobulin heavy-chain variable regions (IGHV) of the BCR. In general, CLL patients with unmutated IGHV have shorter progression-free survival and lower response rates. 2 CLL cells isolated from patients with unmutated IGHV rely heavily on survival signals and respond preferentially to BCR and Toll-like receptor 9 (TLR9) stimulation, 3 suggesting that therapies that block these signals may be particularly effective in this aggressive subset of CLL.
The recently unveiled mechanisms that control CLL cell survival and expansion have prompted the rapid development of therapeutics that disrupt CLL-microenvironment interactions and block BCR-driven activation (that is, fostamatinib, idelalisib and ibrutinib) [4] [5] [6] [7] and have demonstrated profound Letters to the Editor clinical activity. 4, 5 Unfortunately, some patients do not respond or develop resistance, emphasizing the importance of alternative therapeutic strategies. 5 Exportin 1 (XPO1/CRM1) is a nuclear export protein overexpressed in CLL. 8 Nuclear export is emerging as an exciting target as increasing evidence is being generated that nuclearcytoplasmic shuttling proteins have a direct role in the pathophysiology of various hematologic malignancies. 9, 10 We were the first to demonstrate that inhibition of XPO1 by selective inhibitors of nuclear export (SINEs) killed CLL cells in vitro and increased survival in a CLL mouse model. 8 Although nuclear export inhibitors are believed to mediate their effect by forcing mainly nuclear retention and activation of tumor suppressor proteins (that is, p53, FoxO3a, IkB), recent reports also indicate a possible role of SINEs in induction of autophagy and inhibition of ribosomal biogenesis and translational flux. 11, 12 Selinexor is a new clinically viable SINE that is currently in phase I clinical trials for the treatment of both liquid (NCT01607892) and solid tumors (NCT01607905 and NCT01896505). Preliminary data from a cohort of 18 heavily pretreated/refractory non-Hodgkin's lymphoma and CLL patients with progressive disease on study entry indicate that Selinexor is well tolerated with favorable pharmacokinetic, pharmacodynamic and antitumor properties, inducing tumor shrinkage or disease stabilization in 80% of the patients including one ibrutinib/refractory CLL patient with Richter's transformation. 13 To improve our understanding of Selinexor in the setting of CLL therapy, we evaluated survival and tissue homing circuits in vitro and in vivo using validated mouse models of CLL.
Selinexor maintained robust in vitro cytotoxicity in primary CLL cells comparable to its preclinical predecessor KPT-251 ( Figure 1a CLL cells are categorically unresponsive to in vitro stimuli and it is notoriously difficult to assay proliferation ex vivo. However, stimulation via TLR9 using synthetic CpG oligodeoxynucleotides, which mimic bacterial DNA motifs, can occasionally induce limited ex vivo proliferation. 3 This proliferative response is clone dependent and has been correlated with IGHV-unmutated disease for which the magnitude of extracellular-signal-regulated kinase (ERK) and AKT signaling is amplified, leading to upregulation of cyclin A2. To determine whether XPO1 inhibition could abate CpG-induced ex vivo proliferation in unmutated IGHV disease, we treated CpG-stimulated primary CLL cells with Selinexor or vehicle control for 5 days and measured proliferation by 3 H-thymidine incorporation. Selinexor significantly blocked CpG-induced proliferation in the IGHV-unmutated CLL cells ( Figure 1f ). As previously reported, IGHV-mutated CLL cells did not proliferate in response to CpG (data not shown). 3 To delve into the complex molecular mechanism by which XPO1 blockade prevents CpG-induced CLL proliferation, we investigated the effect of Selinexor on TLR9-mediated ERK and AKT survival pathways. CLL cells were stimulated with CpG for 1 h and then treated with Selinexor or vehicle control for additional 1 h or 24 h. Proliferation was confirmed by 3 H-thymidine incorporation after 48 h of treatment (data not shown). Our data reveal that XPO1 inhibition prevents CpG-induced phosphorylation of ERK and AKT, thereby preventing expression of cMyc and cyclin A2 and downstream proliferation of IGHV-unmutated CLL cells (Figures 1f-h ).
Ex vivo BCR crosslinking with immobilized anti-IgM elicits prolonged AKT and ERK phosphorylation, activates CLL cells and protects them from undergoing spontaneous apoptosis. 3 We previously showed that KPT-185 enforces nuclear retention of IkB, leading to inhibition of NF-kB in CLL cells. 8 Among its many functions, NF-kB has been shown to upregulate BTK. 14 Figure 1A) . As BTK is essential to B-lymphocyte development, survival and signaling, we sought to determine the ability of Selinexor to block downstream BCR signaling. After crosslinking the BCR on CLL cells, we analyzed phosphorylation of spleen tyrosine kinase (SYK), AKT and ERK by immunoblot and discovered that Selinexor abrogates phosphorylation of AKT and ERK, but not SYK (Figures 1i and j) , possibly through the targeted inhibition of the AKT or ERK pathways in CLL (for example, downmodulation of BTK), as opposed to nonspecific downmodulation of multiple kinase-mediated pathways.
Interestingly, SINEs induce BTK downmodulation in CLL cells (Supplementary
CXCL12 is a powerful microenvironment recall chemokine that plays key physiologic roles in controlling mature B-and CLL-cell trafficking to germinal centers. 15 In CLL, signaling via the CXCL12/CXCR4 axis drives prolonged activation of the ERK/mitogen-activated protein kinase (MAPK) pathway, reduces spontaneous and drug-induced apoptosis and facilitates the migration of CLL cells beneath stromal cells ex vivo. 6, 15 Our transwell migration assay demonstrates that Selinexor significantly inhibits CXCL12-mediated signaling, preventing recall migration of CLL cells (Figures 1k and l) . Notably, this was not due to downregulation of surface CXCR4 (data not shown).
To validate Selinexor therapeutic efficacy in vivo, we utilized the Em-TCL1-SCID transplant model of CLL. 8 Selinexor or vehicle treatment was initiated after leukemia establishment at 2 weeks post engraftment and we examined two different dosing schedules: (1) BIW (twice per week, Monday and Tuesday) or (2) QoDX3 (three times per week, Monday, Wednesday and Friday). Mice were treated BIW with 5 or 15 mg/kg or QoDX3 with 3, 10 or 15 mg/kg of Selinexor for up to 36 weeks with overall survival (OS) as the primary end point. Surviving animals were followed up for an additional 4 weeks and we observed no indication of leukemic relapse by analysis of the peripheral blood lymphocyte count (data not shown).
Selinexor at doses of 410 mg/kg BIW and QoDX3 significantly prevented the rapid increase of peripheral leukemic cells associated with progressive disease in this model (Supplementary Figures 1B  and C) . Notably, we often do not witness the peripheral lymphocytosis observed with conventional BCR-targeted therapies in clinical trials using the Em-TCL1 model conceivably because the Em-TCL1 model is driven by an aggressive oncogene and not the endogenous BCR.
Within the BIW group, Selinexor at 15 mg/kg showed a significant improvement over vehicle with an impressive 100% survival rate (Figure 2a) . Within the QoDX3 group, Selinexor at 10 and 15 mg/kg QoDX3 both showed a significant improvement over vehicle (Figure 2b) . Selinexor was also effective in mice with leukemic phase (that is, very high tumor burdens) where treatment was initiated 10 weeks post engraftment (Figure 2c and Supplementary Figure 1D ). Volume of spleen is an important metric of disease progression and response to therapy in the Em-TCL1 mouse model of CLL. Selinexor significantly prevented spleen enlargements at doses of 410 mg/kg BIW and QoDX3 (Figures 2d and e ) and in mice with leukemic phase where treatment was initiated 10 weeks post engraftment (Figure 2f) . Overall, Selinexor was also well tolerated and drug-induced weight loss seen at the beginning of the study (Supplementary Figures 1E and F) was fully reversed by the end of the study and did not adversely affect the animals.
To validate our in vitro results, we evaluated the effects of Selinexor on leukemic cell proliferation in vivo using Em-TCL1 transgenic animals. Mice with established leukemia were treated for 2 consecutive days with vehicle control or Selinexor at 15 mg/ kg. The 5-ethynyl-2 0 -deoxyuridine (EdU) was injected on day 3, allowing for incorporation into the genetic material of proliferating cells for 24 h. Afterward, spleen and bone marrow samples were collected for fluorescence-activated cell sorting analysis of proliferating CD5 þ CD19 þ leukemic cells as well as confirmatory Ki67 immunohistochemical staining. Selinexor effectively inhibited the percentage of proliferating leukemic cells (Figures 2g-i) , confirming our in vitro findings that Selinexor can abrogate proliferation of the malignant B cells in vivo. In conclusion, Selinexor was strikingly active in prolonging survival of Em-TCL1-SCID mice. Collectively, our data indicate that XPO1 inhibition prevents BCR-induced survival as well as trafficking of CLL cells to the protective stromal microenvironment. Although these mechanisms warrant further investigation, our data suggest the potential of this clinically viable class of inhibitors to increase sensitivity of CLL cells to current therapies and reduce the likelihood of leukemic relapse.
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B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies Signaling via the aberrantly activated B-cell receptor (BCR) has a critical role in the pathogenesis of B-cell tumors by promoting survival and clonal expansion of malignant B cells. 1, 2 Multiple preclinical studies indicate that blocking various components of the BCR signaling pathway holds a great therapeutic potential in the treatment of B-cell leukemias and lymphomas. 3, 4 This is further supported by clinical data from recent and ongoing clinical trials, which demonstrate considerable activity of SYK inhibitors (fostamatinib and GS-9973), 5 BTK inhibitors (ibrutinib, AVL-292, CC-292 and ONO-4059) 6, 7 and PI3Kd inhibitor (CAL-101) 8 as single agents or in combination with other therapies in patients with B-cell tumors, for whom rituximab-based regimens have become a standard of care. However, tumor relapses occur in a significant percentage of patients treated even with the most effective modalities. Therefore, combinations of anti-CD20 monoclonal antibodies (mAbs) with targeted therapeutics inhibiting BCR signaling pathways have recently become an active area of investigation. For example, ibrutinib and CAL-101 are currently being investigated in combination with chemotherapy and/or anti-CD20 mAbs (rituximab and ofatumumab) in several phase I, II and III clinical trials (summarized in Kharfan-Dabaja et al.
9
). Conspicuously, the antitumor effects of these combinations have not been studied in the preclinical setting. Therefore, we decided to investigate the molecular interactions between anti-CD20 mAbs and R406 (active metabolite of fostamatinib), ibrutinib and CAL-101.
Startlingly, we observed a significant impairment of rituximab-(R-CDC, Figure 1a ) and ofatumumab-induced complement-dependent cytotoxicity (O-CDC) (Supplementary Figure 1a) in Raji cells pre-incubated for 48 h with increasing concentrations of R406, ibrutinib or CAL-101, when compared with controls. The highest tested concentration (1 mM) of R406 and ibrutinib almost completely abrogated both R-CDC and O-CDC, whereas CAL-101 affected anti-CD20 mAb-mediated CDC to a lesser extent. Flow cytometry studies further revealed that pre-incubation of Raji cells with BCR pathway inhibitors severely impaired the binding of various anti-CD20 mAbs (fluorescein isothiocyanate-conjugated L27 clone (Figure 1b) , rituximab and ofatumumab (Figure 1c) ). All three compounds induced a downregulation of surface CD20 levels in a panel of 26 primary chronic lymphocytic leukemia (CLL) samples pre-incubated for 48 h with 1 mM of each BCR signaling inhibitor (Figure 1d ). Since ibrutinib has been recently approved as a secondline monotherapy for patients with mantle cell lymphoma (MCL), we also tested a primary MCL sample and upon treatment with BCR inhibitors observed a significant downregulation of surface CD20 levels and a trend towards impaired R-CDC and O-CDC (Supplementary Figure 1b) . Moreover, we determined the influence of BCR inhibitors on CD20 surface levels in a series of 15 tumor cell lines, including Burkitt's lymphoma (Ramos, Daudi and BJAB), ALL (NALM-6), diffuse large B-cell lymphoma (BCR-dependent Ly-1, Ly-7, Ly-10, DHL-6, HBL-1, U2932 and BCR-independent Ly-4, Ly-19, Pfeiffer) and CLL (EHEB and MEC-1). We observed a significantly decreased surface CD20 levels in most CD20-positive tumor cells irrespectively of the tumor type/subtype (Figure 1e) . Surprisingly, as opposed to the primary CLL samples we did not observe a significant CD20 downregulation in either of the two tested CLL cell lines (Figure 1e ). Since anti-CD20 mAbs are known to also mediate antibody-dependent cell-mediated cytotoxicity (ADCC), 10 we carried out additional analyses to measure the effects of R406, ibrutinib or CAL-101 on ADCC in various settings. Pre-incubation of Raji cells with the increasing concentrations of inhibitors, followed by a coculture with rituximab and NK effector cells in the absence of tested drugs, failed to influence R-ADCC, as determined by CD107a mobilization (Figure 1f) . However, in a clinically more relevant co-incubation model, where both target Raji cells and effector NK cells were cocultured for 4 h in presence of BCR inhibitors, rituximab-induced degranulation of NK cells was severely impaired at 1 mM of R406 or ibrutinib (Figure 1f) . Similarly, in a co-incubation model R406 and ibrutinib inhibited NK cytotoxicity against rituximab- (Figure 1g ) and ofatumumab-opsonized (Supplementary Figure 1c) carboxyfluorescein succinimidyl ester (CFSE)-labeled Raji cells as assessed using flow cytometry. Moreover, the release of tumor necrosis factor (TNF) and interferon (IFN)-g from NK cells incubated with either R406 or ibrutinib was severely impaired (Figure 1h) . Noteworthy, even the highest concentrations of all tested BCR inhibitors did not affect the viability of NK cells in a 48-h culture (Supplementary Figure 1d) . Conspicuously, CAL-101 exerted no antagonistic effect on NK cell cytotoxicity, CD107a mobilization and cytokine secretion in a co-incubation model. This is in accordance with a study by Herman et al., 11 where CAL-101 was reported not to interfere with rituximab-mediated or alemtuzumabmediated ADCC, although it diminished IFN-g production by NK cells.
The levels of complement regulatory proteins (CD46 and CD55) as well as other B-cell surface antigens (CD38 and CD19) remained roughly unchanged upon treatment with BCR inhibitors (Supplementary Figure 2) . However, we observed a significant downregulation of CD21 and CD22, of which CD22 is currently used as a target for toxin-conjugated anti-CD22 mAbs (inotuzumab ozogamicin). Thus, our results may suggest that CD20 downregulation is not an isolated phenomenon and BCR Accepted article preview online 10 January 2014; advance online publication, 4 February 2014
